1 completed, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Stage IIIA Melanoma: new trials by email Literature Review of Stage IIIA Melanoma trials Research Report on Stage IIIA Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 17 | 2014-12-01 | 2018-07-03 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2013-05-01 | 2014-09-25 |
Melanoma (2) · Carcinoma, Renal Cell (1) · Pancreatic Neoplasms (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Skin Diseases (2) · Skin Neoplasms (2) · Skin and Connective Tissue Diseases (2) · Adenocarcinoma (1) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
Vemurafenib (1) · cabozantinib (1)
National Cancer Institute (NCI) (1) · Wake Forest University Health Sciences (1)
United States (2)
Jason Luke (1) · Pierre Triozzi (1)
P30CA006516 (1), P30CA012197 (1), U01CA062490 (1), UM1CA186709 (1)